Cargando…

TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge

PURPOSE: TP53germline (g) mutations, associated with the Li-Fraumeni syndrome (LFS), have rarely been reported in the context of hereditary breast and ovarian cancer (HBOC). The prevalence and cancer risks in this target group are unknown and counseling remains challenging. Notably an extensive high...

Descripción completa

Detalles Bibliográficos
Autores principales: Grill, Sabine, Ramser, Juliane, Hellebrand, Heide, Pfarr, Nicole, Boxberg, Melanie, Brambs, Christine, Ditsch, Nina, Meindl, Alfons, Groß, Eva, Meitinger, Thomas, Kiechle, Marion, Quante, Anne S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087555/
https://www.ncbi.nlm.nih.gov/pubmed/33245408
http://dx.doi.org/10.1007/s00404-020-05883-x
_version_ 1783686688228245504
author Grill, Sabine
Ramser, Juliane
Hellebrand, Heide
Pfarr, Nicole
Boxberg, Melanie
Brambs, Christine
Ditsch, Nina
Meindl, Alfons
Groß, Eva
Meitinger, Thomas
Kiechle, Marion
Quante, Anne S.
author_facet Grill, Sabine
Ramser, Juliane
Hellebrand, Heide
Pfarr, Nicole
Boxberg, Melanie
Brambs, Christine
Ditsch, Nina
Meindl, Alfons
Groß, Eva
Meitinger, Thomas
Kiechle, Marion
Quante, Anne S.
author_sort Grill, Sabine
collection PubMed
description PURPOSE: TP53germline (g) mutations, associated with the Li-Fraumeni syndrome (LFS), have rarely been reported in the context of hereditary breast and ovarian cancer (HBOC). The prevalence and cancer risks in this target group are unknown and counseling remains challenging. Notably an extensive high-risk surveillance program is implemented, which evokes substantial psychological discomfort. Emphasizing the lack of consensus about clinical implications, we aim to further characterize TP53g mutations in HBOC families. METHODS: Next-generation sequencing was conducted on 1876 breast cancer (BC) patients who fulfilled the inclusion criteria for HBOC. RESULTS: (Likely) pathogenic variants in TP53 gene were present in 0.6% of the BC cohort with higher occurrence in early onset BC < 36 years. (1.1%) and bilateral vs. unilateral BC (1.1% vs. 0.3%). Two out of eleven patients with a (likely) pathogenic TP53g variant (c.542G > A; c.375G > A) did not comply with classic LFS/Chompret criteria. Albeit located in the DNA-binding domain of the p53-protein and therefore revealing no difference to LFS-related variants, they only displayed a medium transactivity reduction constituting a retainment of wildtype-like anti-proliferative functionality. CONCLUSION: Among our cohort of HBOC families, we were able to describe a clinical subgroup, which is distinct from the classic LFS-families. Strikingly, two families did not adhere to the LFS criteria, and functional analysis revealed a reduced impact on TP53 activity, which may suit to the attenuated phenotype. This is an approach that could be useful in developing individualized screening efforts for TP53g mutation carrier in HBOC families. Due to the low incidence, national/international cooperation is necessary to further explore clinical implications. This might allow providing directions for clinical recommendations in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00404-020-05883-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8087555
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-80875552021-05-05 TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge Grill, Sabine Ramser, Juliane Hellebrand, Heide Pfarr, Nicole Boxberg, Melanie Brambs, Christine Ditsch, Nina Meindl, Alfons Groß, Eva Meitinger, Thomas Kiechle, Marion Quante, Anne S. Arch Gynecol Obstet Gynecologic Oncology PURPOSE: TP53germline (g) mutations, associated with the Li-Fraumeni syndrome (LFS), have rarely been reported in the context of hereditary breast and ovarian cancer (HBOC). The prevalence and cancer risks in this target group are unknown and counseling remains challenging. Notably an extensive high-risk surveillance program is implemented, which evokes substantial psychological discomfort. Emphasizing the lack of consensus about clinical implications, we aim to further characterize TP53g mutations in HBOC families. METHODS: Next-generation sequencing was conducted on 1876 breast cancer (BC) patients who fulfilled the inclusion criteria for HBOC. RESULTS: (Likely) pathogenic variants in TP53 gene were present in 0.6% of the BC cohort with higher occurrence in early onset BC < 36 years. (1.1%) and bilateral vs. unilateral BC (1.1% vs. 0.3%). Two out of eleven patients with a (likely) pathogenic TP53g variant (c.542G > A; c.375G > A) did not comply with classic LFS/Chompret criteria. Albeit located in the DNA-binding domain of the p53-protein and therefore revealing no difference to LFS-related variants, they only displayed a medium transactivity reduction constituting a retainment of wildtype-like anti-proliferative functionality. CONCLUSION: Among our cohort of HBOC families, we were able to describe a clinical subgroup, which is distinct from the classic LFS-families. Strikingly, two families did not adhere to the LFS criteria, and functional analysis revealed a reduced impact on TP53 activity, which may suit to the attenuated phenotype. This is an approach that could be useful in developing individualized screening efforts for TP53g mutation carrier in HBOC families. Due to the low incidence, national/international cooperation is necessary to further explore clinical implications. This might allow providing directions for clinical recommendations in the future. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00404-020-05883-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-11-27 2021 /pmc/articles/PMC8087555/ /pubmed/33245408 http://dx.doi.org/10.1007/s00404-020-05883-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gynecologic Oncology
Grill, Sabine
Ramser, Juliane
Hellebrand, Heide
Pfarr, Nicole
Boxberg, Melanie
Brambs, Christine
Ditsch, Nina
Meindl, Alfons
Groß, Eva
Meitinger, Thomas
Kiechle, Marion
Quante, Anne S.
TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title_full TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title_fullStr TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title_full_unstemmed TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title_short TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
title_sort tp53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087555/
https://www.ncbi.nlm.nih.gov/pubmed/33245408
http://dx.doi.org/10.1007/s00404-020-05883-x
work_keys_str_mv AT grillsabine tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT ramserjuliane tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT hellebrandheide tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT pfarrnicole tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT boxbergmelanie tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT brambschristine tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT ditschnina tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT meindlalfons tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT großeva tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT meitingerthomas tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT kiechlemarion tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge
AT quanteannes tp53germlinemutationsinthecontextoffamilieswithhereditarybreastandovariancanceraclinicalchallenge